Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback